Press "Enter" to skip to content

Hikma core operating profit jumps on higher sales of injectable drugs

The Jordan-based drugmaker said its core operating profit rose to $460 million for the year ended Dec. 31 from $386 million a year earlier.

Original source:

Also Read:   AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval